Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Inovio Pharmaceuticals Inc (NASDAQ: INO) closed the day trading at $1.71 down -8.06% from the previous closing price of $1.86. In other words, the price has decreased by -$8.06 from its previous closing price. On the day, 0.57 million shares were traded.
Ratios:
For a better understanding of INO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.77 and its Current Ratio is at 2.77. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on May 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $20.
On January 25, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $4.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 285.04 while its Price-to-Book (P/B) ratio in mrq is 0.90.
Stock Price History:
Over the past 52 weeks, INO has reached a high of $13.44, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is -6.64%, while the 200-Day Moving Average is calculated to be -59.65%.
Shares Statistics:
A total of 36.67M shares are outstanding, with a floating share count of 36.42M. Insiders hold about 0.69% of the company’s shares, while institutions hold 38.81% stake in the company.
Earnings Estimates
The current assessment of Inovio Pharmaceuticals Inc (INO) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.55 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$2.12 and -$2.96 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$2.35, with 4.0 analysts recommending between -$1.37 and -$3.25.
Revenue Estimates
Based on 5 analysts’ estimates, the company’s revenue will be $21.6M in the next fiscal year. The high estimate is $58.66M and the low estimate is $9.9M.
